---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-25-000130"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:24:36.399989+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Xeris Biopharma Q2 revenue up 49% to $71.5M; Recorlev +136%; raises FY guidance to $280-290M

## Summary
- Total revenue $71.5M (+49% YoY); net loss narrowed to $1.9M ($0.01/sh) from $15M ($0.10/sh).
- Recorlev net revenue $31.4M (+136%) driven by 122% increase in average patients on therapy.
- Gvoke revenue $23.5M (+17%); Keveyis $11.5M (-13%) on reduced shipments.
- Adjusted EBITDA improved to $12.5M vs -$0.4M in Q2 2024.
- Raised FY 2025 revenue guidance to $280-290M from $260-275M; long-term target $750M by 2030.

## SEC filing metadata
- accession: 0001867096-25-000130
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000130/0001867096-25-000130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000130/xers-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-25-000130
- JSON: https://secwatch.observer/filing/0001867096-25-000130.json
- Plain text: https://secwatch.observer/filing/0001867096-25-000130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.